Prima Biomed to Present at BIOX
Published: Sep 24, 2012
SYDNEY, AUSTRALIA--(Marketwire - September 21, 2012) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (Prima, the Company) announces that its CEO Matthew Lehman will present a corporate update at BIOX; Noble Financial Capital Markets' Life Sciences Exposition to be held at the University of Connecticut, Stamford Campus (USA) on September 24-25, 2012.
Following the event, a high-definition video webcast of Prima's presentation and a copy of the presentation materials will be available on the Company's web site (www.primabiomed.com.au), or through the Noble Financial websites: www.noblefcm.com, or www.nobleresearch.com/BioExposition.htm. You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate.
About Prima BioMed
Prima BioMed is a globally active biotechnology company headquartered in Australia. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.
About Noble Financial
Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service, investment banking boutique focused on life sciences, technology and media, emerging growth, companies. The company has offices in New York, Boston, New Jersey, Los Angeles, and Boca Raton, FL. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial hosts its large format annual equity conference in January in South Florida featuring 150 presenting companies from across North America and total attendance of close to 600. For more information: www.noblefcm.com.
For further information please contact:
Mr. James Moses
+61 (0) 420 991 574
Ms. Kathy Galante
Burns McClellan Inc.
+1 (212) 213-0006
Mr. Axel Muhlhaus
+49 (0) 69 905505-52